Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.67 Analyst target: $6.10 Upside: 128.46%
Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.